Adaptive Biotechnologies receives expanded Medicare coverage of clonoSEQ

Adaptive Biotechnologies (ADPT) announced that Palmetto GBA, a Medicare Administrative Contractor, MAC, that assesses diagnostic technologies through its Molecular Diagnostics Services Program, MoIDX, has expanded coverage of clonoSEQ to include detection and monitoring of measurable residual disease, MRD, in Medicare patients with mantle cell lymphoma